Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report

• Published in: Case reports in oncology Vol. 6; no. 2; pp. 275 - 279
• Main Authors: Kawasaki, Atsushi, Mimatsu, Kenji, Oida, Takatsugu, Kano, Hisao, Kuboi, Youichi, Fukino, Nobutada, Kida, Kazutoshi, Amano, Sadao
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 18.05.2013; Karger Publishers
• Subjects: Colorectal cancer; Panitumumab; Portal vein tumor thrombosis; Published: May 2013; Portal vein tumor thrombosis; Panitumumab; Colorectal cancer
• ISSN: 1662-6575; 1662-6575
• DOI: 10.1159/000343680

The patient was a male in his 70s with a history of chronic renal failure and dilated cardiomyopathy. In January 2011, he underwent abdominoperineal resection of the rectum, right hepatic lobectomy, and resection of a portal vein tumor thrombus with a diagnosis of rectal cancer and metastatic liver cancer accompanied by portal vein tumor thrombosis. Although 5-fluorouracil + l-leucovorin therapy (RPMI regimen) was carried out as postoperative adjuvant chemotherapy, the tumor marker (CEA and VA19-9) levels increased 8 months after surgery. Since the functions of major organs were impaired, UFT® + UZEL® therapy was started. The tumor marker levels decreased temporarily, but increased again 12 months after surgery, and so intravenous instillation of panitumumab was initiated. Nine administrations have been performed to date, with no increase in tumor marker levels or exacerbation of the condition. Also, no grade 2 or severer adverse event has been noted according to CTCAE v.4.0. The experience with this patient suggests the possibility that exacerbation of the condition of patients with liver metastasis of colorectal cancer accompanied by portal vein tumor thrombosis with abnormalities in the functions of major organs can be controlled temporarily by the administration of panitumumab alone.